Nothing Special   »   [go: up one dir, main page]

SI1248600T1 - Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV - Google Patents

Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV

Info

Publication number
SI1248600T1
SI1248600T1 SI200030994T SI200030994T SI1248600T1 SI 1248600 T1 SI1248600 T1 SI 1248600T1 SI 200030994 T SI200030994 T SI 200030994T SI 200030994 T SI200030994 T SI 200030994T SI 1248600 T1 SI1248600 T1 SI 1248600T1
Authority
SI
Slovenia
Prior art keywords
hiv protease
pharmaceutical formulations
protease inhibitors
improved hiv
improved
Prior art date
Application number
SI200030994T
Other languages
English (en)
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1248600(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SI1248600T1 publication Critical patent/SI1248600T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
SI200030994T 2000-01-19 2000-12-01 Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV SI1248600T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
EP00982360A EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations
PCT/US2000/032771 WO2001052821A1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SI1248600T1 true SI1248600T1 (sl) 2008-08-31

Family

ID=23936923

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200031073T SI1917958T1 (sl) 2000-01-19 2000-12-01 Izpopolnjene farmacevtske formulacije inhibitorjev HIV proteaze
SI200031095T SI2269591T1 (sl) 2000-01-19 2000-12-01 Izboljšane farmacevtske formulacije
SI200030994T SI1248600T1 (sl) 2000-01-19 2000-12-01 Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200031073T SI1917958T1 (sl) 2000-01-19 2000-12-01 Izpopolnjene farmacevtske formulacije inhibitorjev HIV proteaze
SI200031095T SI2269591T1 (sl) 2000-01-19 2000-12-01 Izboljšane farmacevtske formulacije

Country Status (26)

Country Link
EP (3) EP1917958B1 (sl)
JP (1) JP4769400B2 (sl)
KR (1) KR100861885B1 (sl)
CN (1) CN100536833C (sl)
AT (1) ATE395049T1 (sl)
AU (2) AU1940501A (sl)
BG (1) BG66112B1 (sl)
BR (1) BR0011864A (sl)
CA (1) CA2395987C (sl)
CY (3) CY1108197T1 (sl)
CZ (1) CZ304118B6 (sl)
DE (1) DE60038899D1 (sl)
DK (3) DK2269591T3 (sl)
ES (3) ES2304990T3 (sl)
HK (1) HK1120213A1 (sl)
HU (1) HU229778B1 (sl)
IL (2) IL150265A0 (sl)
MX (1) MXPA02007097A (sl)
NO (1) NO331400B1 (sl)
NZ (1) NZ519724A (sl)
PT (3) PT1248600E (sl)
SI (3) SI1917958T1 (sl)
SK (1) SK287143B6 (sl)
TR (1) TR201809435T4 (sl)
WO (1) WO2001052821A1 (sl)
ZA (1) ZA200205109B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) * 2007-08-07 2009-02-12 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DE69133463T2 (de) 1990-11-19 2006-07-27 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Retrovirusprotease Inhibitoren
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
SK280882B6 (sk) 1991-10-11 2000-08-14 The Du Pont Merck Pharmaceutical Company Cyklické močoviny, ich analógy a farmaceutické prípravky na ich báze
NZ244986A (en) 1991-11-08 1995-10-26 Merck & Co Inc Hiv protease inhibitor and pharmaceutical compositions
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0560268T3 (da) 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
DE69304051T2 (de) 1992-05-20 1997-01-23 Monsanto Co Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1997021683A1 (en) * 1995-12-13 1997-06-19 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
DE60029219T2 (de) * 1999-06-04 2007-06-28 Abbott Laboratories, Abbott Park Verbesserte arzneizubereitungen enthaltend ritonavir

Also Published As

Publication number Publication date
AU2006235895B2 (en) 2009-08-13
SI2269591T1 (sl) 2018-08-31
DE60038899D1 (de) 2008-06-26
EP2269591A2 (en) 2011-01-05
CZ20022663A3 (cs) 2002-11-13
IL150265A0 (en) 2002-12-01
IL150265A (en) 2015-02-26
MXPA02007097A (es) 2003-01-28
CN1424907A (zh) 2003-06-18
EP1248600B1 (en) 2008-05-14
PT1917958E (pt) 2012-08-16
HUP0302070A2 (hu) 2003-09-29
ES2387579T3 (es) 2012-09-26
NO20023455L (no) 2002-09-18
JP2003533435A (ja) 2003-11-11
ES2304990T3 (es) 2008-11-01
CA2395987A1 (en) 2001-07-26
EP1917958A3 (en) 2008-08-27
HK1120213A1 (en) 2009-03-27
HUP0302070A3 (en) 2007-02-28
SK287143B6 (sk) 2010-01-07
PL361396A1 (en) 2004-10-04
CN100536833C (zh) 2009-09-09
ZA200205109B (en) 2003-10-31
NO20023455D0 (no) 2002-07-18
DK1917958T3 (da) 2012-09-24
EP2269591A3 (en) 2011-07-27
SI1917958T1 (sl) 2012-10-30
EP1917958A2 (en) 2008-05-07
EP1917958B1 (en) 2012-06-13
AU1940501A (en) 2001-07-31
SK11102002A3 (sk) 2002-12-03
AU2006235895A1 (en) 2006-11-30
PT1248600E (pt) 2008-08-25
HU229778B1 (hu) 2014-07-28
JP4769400B2 (ja) 2011-09-07
CY1120408T1 (el) 2019-07-10
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
BR0011864A (pt) 2004-07-20
EP1248600A1 (en) 2002-10-16
NZ519724A (en) 2004-07-30
WO2001052821A1 (en) 2001-07-26
BG66112B1 (bg) 2011-05-31
EP2269591B1 (en) 2018-04-04
CY1112995T1 (el) 2016-04-13
KR20020082210A (ko) 2002-10-30
KR100861885B1 (ko) 2008-10-09
CA2395987C (en) 2009-12-22
ATE395049T1 (de) 2008-05-15
TR201809435T4 (tr) 2018-07-23
BG106976A (bg) 2003-05-30
PT2269591T (pt) 2018-07-09
CZ304118B6 (cs) 2013-11-06
CY1108197T1 (el) 2014-02-12
DK2269591T3 (en) 2018-07-16
NO331400B1 (no) 2011-12-19

Similar Documents

Publication Publication Date Title
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
PL350075A1 (en) Taxane formulations having improved solubility
ZA200302389B (en) Oral dosage self-emulsifying formulations of pyranone protease inhibitors.
HUP0200995A3 (en) Taxane formulations having improved solubility
IL126185A0 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
MXPA03004534A (es) Compuestos novedosos para su uso como inhibidores de la proteasa del virus de inmunodeficiencia humana (vih).
HK1047933A1 (zh) 具有改善的溶解度的紫杉烷製劑
IL136321A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives